CLINICAL TRIAL: ONCE DAILY REGIMEN OF DIDANOSINE, TENOFOVIR AND EFAVIRENZ

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的主要目的是（1）确定艾滋病毒感染如何在身体的各个部位发展（包括血液、精液、阴道分泌物和脊髓液）以及身体对新感染的反应，（2）了解每天一次抗逆转录病毒联合治疗对新感染艾滋病毒者的安全性和耐受性，并观察这种治疗如何限制对免疫系统的损害，以及（3）确定新感染者中耐药病毒的频率，以及它们如何以及是否影响对治疗的反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purposes of the study are (1) to determine how HIV infection develops at various sites in the body (including blood, semen, vaginal secretions and spinal fluid) and how the body responds to new infection, (2) to find out how safe and well tolerated once a day dosing of combination antiretroviral treatment is for new HIV infected persons, and to see how well this treatment limits the damage to teh immune system, and (3) to determine the frequency of resistant viruses in newly infected persons and how and if they affect response to treatment.